Interferon therapy in an infant with Kasabach-Merritt syndrome.
An infant with Kasabach-Merritt syndrome was treated with interferon-alfa 2b. Clinical and hematological responses were followed. Intron-A (Schering-Plough) was administered to a two and half-month-old male infant after failure of most other conventional therapies. A daily dose of 100,000 u/Kg was given subcutaneously for a total of 122 days. Clinical and laboratory aggravation was observed in the first eight days. The fibrinogen level increased to > 100 mg/dl after two weeks of Intron-A treatment. Local inflammatory signs began to improve after 21 days. The platelet count became normal after 80 days of treatment. During follow-up, there was continuous regression of the tumor.
Yeh
K W
KW
Department of Pediatrics, Chang-Gung Memorial Hospital, Chang-Gung Medical College, Tao-Yuan, Taiwan, R.O.C.
Jiang
T H
TH
Hung
I J
IJ
D006391:Hemangioma / Q000628:therapy*; D006801:Humans; D007223:Infant; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D011994:Recombinant Proteins; D013577:Syndrome; D013921:Thrombocytopenia / Q000628:therapy*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins